Molecule News and Research

RSS

Oncotarget: mi R-151a overexpression enhances tumor-associated angiogenesis

Volume 11, Issue 23 of @Oncotarget reported that the authors have previously established that mi R-151a functions as an onco-mi R in non-small cell lung cancer cells by inducing partial EMT and enhancing tumor growth.

10 Jun 2020

Study provides molecular explanation to a longstanding mystery in viral oncology

The oncogenic herpesvirus (HHV8 or KSHV) causes a cancer known as Kaposi's Sarcoma. An international team of scientists led by the University of Helsinki has discovered key factors that control the genome maintenance and replication of a virus responsible for lymphatic vascular cancer.

10 Jun 2020

A drug to treat harsh complications of coronavirus infection is registered in Russia

Levilimab received state approval through a fast-track mechanism, according to Decree No. 441 of the Government of the Russian Federation of April 4, 2020, since its mechanism of action is associated with the control of the cytokine storm, which is one of the manifestations of coronavirus infection.

9 Jun 2020

Study sheds new light on memory impairment in Alzheimer's disease

Neurons that are responsible for new experiences interfere with the signals of neurons that contain memories and thereby disturb the recall of memories - at least in mice.

9 Jun 2020

Study reveals new strategy to tackle cancer

A study led by the Institut de Neurociències describes a new strategy to tackle cancer, based on inducing a potent stress in tumor causing cell destruction by autophagy.

9 Jun 2020

Protease inhibition could help defeat SARS-CoV-2

As the COVID-19 pandemic caused by the coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to spread around the world, many researchers are studying epidemiological models to predict its propagation. As of yet, there are no effective vaccines that could counter the SARS- CoV-2 infection or drugs to treat COVID-19 disease

9 Jun 2020

Anti-RBD antibodies shown to neutralize active SARS-CoV-2

A new study published on the preprint server bioRxiv* in June 2020 reports the discovery of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in samples from healthy donors, collected before the pandemic. These antibodies are capable of inhibiting the binding of the spike protein of the virus to the angiotensin-converting enzyme 2 (ACE2) molecule and can neutralize active infection of cells in culture.

9 Jun 2020

Metabolic diseases alter ACE2 expression and increase COVID-19 severity

A new study published on the preprint server medRxiv in June 2020 reports that one mechanism for this variable severity is the differential expression of the ACE2 receptor in various metabolic conditions, thereby facilitating viral entry into the host cells.

9 Jun 2020

New study shows possible alternative pathway of SARS-CoV-2 infection in overactive bladder

A new study published on the preprint server bioRxiv*, in June 2020, reports that the condition of overactive bladder (OAB) could be associated with a different route of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19 disease.

8 Jun 2020

Virginia Tech researcher develops new ‘fat burning’ molecule with potential to treat obesity

Obesity affects more than 40 percent of adults in the United States and 13 percent of the global population.

8 Jun 2020

Inhibition of coronavirus spike protein binding to ACE2

A novel coronavirus, CoV-19, and a later phenotype CoV-2 were identified as the primary cause for severe acute respiratory syndrome (SARS CoV-2). The spike (S) protein of CoV-2 is one target for the development of a vaccine to prevent the viral entry into human cells. The inhibition of the direct interaction between ACE2 and the S-protein could provides a suitable strategy to prevent the membrane fusion of CoV-2 and the viral entry into human cells. Using MD simulations, we investigate the assembly process of a Coronavirus Spike protein fragment, the hexapeptide YKYRYL on the ACE2 receptor and its inhibitzory effect on the aggregation and activation of the CoV-2 spike receptor protein at the same receptor protein.

8 Jun 2020

SARS-CoV-2 invasion of central nervous system through olfactory tract

As the COVID-19 pandemic continues to claim lives throughout the world, the evidence is mounting that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract as well as the central nervous system. Now, a new study by German researchers published on the preprint server bioRxiv in June 2020 describes various neurological manifestations of COVID-19, as well as the underlying pathophysiology.

7 Jun 2020